Glucoză Stada Hemofarm

Glucoză Stada Hemofarm is an intravenous preparation that contains glucose monohydrate as its active ingredient. It is marketed in the European Union and supplied as a sterile solution for infusion. The product is intended for use by healthcare professionals to provide a rapid source of carbohydrate energy when administered directly into the bloodstream. The formulation follows standards for purity and isotonicity, and it is packaged in vials to maintain sterility.

Glucoză Stada Hemofarm is used in clinical settings where rapid glucose supplementation is required.

- Correction of acute hypoglycemia in patients who cannot take oral glucose, such as those who are unconscious or intubated. - Supplementation of carbohydrate calories during operative procedures or anesthesia to maintain blood glucose stability. - Adjunct to total parenteral nutrition regimens, providing a readily available source of glucose for metabolic needs. - Assistance in the management of electrolyte disturbances that may accompany low plasma glucose levels, such as potassium shifts. - Facilitation of certain diagnostic tests, for example glucose tolerance assessments, where a precise intravenous glucose dose is required.

When administered intravenously, glucose monohydrate can produce a range of physiological responses, most of which are mild and transient.

Common: - Temporary feeling of warmth or flushing at the infusion site. - Mild nausea or abdominal discomfort. - Transient increase in blood glucose levels. - Headache or dizziness, especially if administered rapidly.

Serious: - Hyperglycemia leading to osmotic diuresis. - Hypotension due to rapid infusion of hypotonic solution. - Allergic reactions such as rash, itching, or anaphylaxis. - Electrolyte imbalance, particularly low potassium (hypokalemia). - Pulmonary edema in patients with compromised cardiac function.

Healthcare providers should observe several precautions before and during the administration of Glucoză Stada Hemofarm to ensure patient safety.

- Verify patient’s blood glucose level and overall metabolic status prior to infusion. - Use aseptic technique and inspect the solution for particulate matter or discoloration. - Adjust infusion rate according to patient age, weight, and cardiac function. - Monitor vital signs and blood glucose frequently during and after administration. - Avoid use in patients with known hypersensitivity to glucose solutions. - Consider renal or hepatic impairment, which may affect glucose metabolism. - Ensure compatible IV fluids are used to prevent precipitation.

Glucose monohydrate may interact with other intravenous agents or medications, influencing their efficacy or safety.

Avoid: - Co‑administration with rapid‑acting insulin without close glucose monitoring. - Simultaneous infusion of high‑dose potassium chloride, which can increase the risk of hyperkalemia. - Mixing with calcium‑containing solutions that may cause precipitation.

Use with caution: - Concurrent use of diuretics that can alter electrolyte balance. - Administration alongside beta‑blockers, which may mask signs of hypoglycemia. - Use in patients receiving corticosteroids, as they can raise blood glucose levels. - Combination with other hyperosmolar solutions, requiring careful monitoring of fluid status.